TABLE 4.

Summary data for patients shedding ACV-resistant virus^a

Immune status	Patient no.	Disease status	Isolation site	Virus type	Phenotype	IC50 (μM)	Treatment history	Dose
Immunocompetent	1	Genital	Genital	2	UC	12	None
	2	Genital	Genital	2	TKD	18	ACV cream
	3	Genital	Genital	2	TKA	5.5	None
	4	Genital	Genital	2	UC	19	None
	5	Keratitis	Eye	2	TKD	110	No information
Immunocompromised	6	HIV positive	Genital	1	TKD	22	Prophylaxis (oral)	400 mg BID
	7	Lung transplant	Lung	1	TKD	43	Prophylaxis (oral)	200 mg BID
	8	AML	Oral	1	TKD	19	Treatment (oral)	Not known
	9	BMT	Oral	1	TKA	40	Treatment (oral)	200 mg QID
	10	BMT	Oral	1	TKD	11	Prophylaxis (oral)	200 mg 5× daily
	11	Heart transplant	Oral	1	TKD	3	Treatment (oral)b	200 mg TID

^aAbbreviations: UC, uncharacterized phenotype; BID, twice daily; QID, four times daily; TID, three times daily; AML, acute myelocytic leukemia; BMT, bone marrow transplant. 

^bThis patient also received ganciclovir.